Comment

  • 29 August 2019

    Glenmark wins regulatory approval to market diabetes drug in India

    Glenmark Pharmaceuticals has achieved regulatory approval in India for its novel type 2 diabetes (T2D) combinatorial drug. The therapy consists of remogliflozin etabonate—a sodium-glucose cotransporter-2 (SGLT-2) inhibitor—and metformin hydrochloride.

Close
Close
Close